Nerandomilast (Jascayd)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Idiopathic Pulmonary Fibrosis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Systemic Sclerosis · Phase 3

Also approved (5)
US
  • Progressive pulmonary fibrosis (PPF) in adult patients
Product first approved 2025Outside this platform's coverageFDA label
EU
  • Jascayd is indicated for the treatment of adult patients with Idiopathic Pulmonary Fibrosis (IPF). Jascayd is indicated for the treatment of adult patients with Progressive Pulmonary Fibrosis (PPF).
Product first approved 2026EMA
JP
  • Adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF)
Product first approved 2026pharmafocuseurope.com
CN
  • Adults with progressive pulmonary fibrosis (PPF)Outside this platform's coverage
  • Idiopathic pulmonary fibrosis (IPF)
Product first approved 2025biospace.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (9)
Idiopathic Pulmonary Fibrosis
Systemic Sclerosis
NCT07497087 · Boehringer Ingelheim
2026-07-27 – 2030-03-17 · Systemic Sclerosis
What this study did
Other / comorbidity
NCT07366034 · Boehringer Ingelheim
2026-07-21 – 2031-04-14 · Fibrosing Interstitial Lung Disease
What this study did
NCT07789015 · Boehringer Ingelheim
2026-12-14 – 2030-04-04 · Idiopathic Inflammatory Myopathies
What this study did
NCT07201922 · Boehringer Ingelheim
2026-02-10 – 2029-05-23 · Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
What this study did
NCT07540988 · Boehringer Ingelheim
2026-09-17 – 2028-12-12 · Interstitial Lung Diseases
What this study did
NCT06806592 · Boehringer Ingelheim
2025-09-13 – 2027-04-28 · Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
What this study did
NCT05321082 · Boehringer Ingelheim
2022-11-16 – 2025-04-14 · Lung Diseases, Interstitial
What this study did
Phase 2/3 (1)
Phase 2 (3)
Idiopathic Pulmonary Fibrosis
NCT06241560 · Boehringer Ingelheim
2026-03-05 – 2026-08-07 · Idiopathic Pulmonary Fibrosis
What this study did
Other / comorbidity
NCT06195072 · Scleroderma Research Foundation, Inc.
2024-04-15 – 2026-11 · Interstitial Lung Disease Due to Systemic Disease, Scleroderma
What this study did
Phase 1 (23)
Idiopathic Pulmonary Fibrosis
Other / comorbidity
NCT07081932 · Boehringer Ingelheim
2025-08-26 – 2025-10-08 · Healthy
What this study did
NCT07100964 · Boehringer Ingelheim
2025-08-11 – 2025-10-01 · Healthy
What this study did
NCT06624072 · Boehringer Ingelheim
2024-10-15 – 2024-11-30 · Healthy
What this study did
NCT06393127 · Boehringer Ingelheim
2024-06-04 – 2024-09-10 · Healthy
What this study did
NCT06408870 · Boehringer Ingelheim
2024-06-06 – 2024-08-28 · Healthy
What this study did
NCT06107036 · Boehringer Ingelheim
2024-03-06 – 2024-07-25 · Healthy
What this study did
NCT06415045 · Boehringer Ingelheim
2024-05-28 – 2024-07-24 · Healthy
What this study did
NCT06139302 · Boehringer Ingelheim
2023-12-20 – 2024-02-13 · Healthy
What this study did
NCT06070610 · Boehringer Ingelheim
2023-11-08 – 2023-12-14 · Healthy
What this study did
NCT05661344 · Boehringer Ingelheim
2023-02-07 – 2023-09-13 · Hepatic Insufficiency
What this study did
NCT05718648 · Boehringer Ingelheim
2023-02-09 – 2023-08-15 · Renal Insufficiency, Healthy
What this study did
NCT05707403 · Boehringer Ingelheim
2023-02-14 – 2023-03-28 · Healthy
What this study did
NCT05633862 · Boehringer Ingelheim
2023-01-13 – 2023-03-17 · Healthy
What this study did
NCT05550636 · Boehringer Ingelheim
2022-10-11 – 2022-12-19 · Healthy
What this study did
NCT05428436 · Boehringer Ingelheim
2022-08-15 – 2022-09-30 · Healthy
What this study did
NCT04771286 · Boehringer Ingelheim
2021-03-25 – 2021-05-17 · Healthy
What this study did
NCT03403439 · Boehringer Ingelheim
2018-05-03 – 2018-07-20 · Healthy
What this study did
NCT03230487 · Boehringer Ingelheim
2017-08-10 – 2018-01-16 · Healthy
What this study did
NCT03302078 · Boehringer Ingelheim
2017-10-16 – 2017-12-13 · Healthy
What this study did
NCT01835899 · Boehringer Ingelheim
2013-04 – 2013-06 · Healthy
What this study did
NCT01594515 · Boehringer Ingelheim
2012-05 – 2012-09 · Healthy
What this study did
Phase 4 (1)
Other / comorbidity

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Idiopathic Pulmonary Fibrosis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Nerandomilast (Jascayd): this drugApprovedSmall moleculePDE4BReliable signal
NCT05321069: Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 (The MMRM model is a longitudinal analysis, and it incorporated FVC measurements from baseline (Week -8 to Week -1) and Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52): Placebo -183.48 Milliliters (mL) (95% CI -210.86 to -156.1) | Nerandomilast 9 mg BID -138.6 Milliliters (mL) (95% CI -165.59 to -111.61) | Nerandomilast 18 mg BID -114.65 Milliliters (mL) (95% CI -141.81 to -87.5)
NCT04419506: The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks (Baseline (day 1) and week 12.): Placebo - Antifibrotics at Baseline -77.7 Milliliter (95% CI -124.87 to -30.53) | BI 1015550 - Antifibrotics at Baseline 2.72 Milliliter (95% CI -33.46 to 38.89) | Placebo - Non-antifibrotics at Baseline -95.62 Milliliter (95% CI -157.13 to -34.1) | BI 1015550 - Non-antifibrotics at Baseline 6.1 Milliliter (95% CI -39.67 to 51.88)
Nintedanib (Ofev)ApprovedSmall moleculeTriple angiokinase inhibitor (VEGFR/FGFR/PDGFR)Partial signal
NCT01335464: INPULSIS-1, annual rate of FVC decline over 52 weeks, nintedanib 150 mg twice daily (n=309) vs placebo (n=204): -114.65 vs -239.91 mL/year; difference 125.26 mL/year (95% CI 77.68 to 172.84), p < 0.0001 (CT.gov posted results).
NCT01335477: INPULSIS-2, annual rate of FVC decline over 52 weeks, nintedanib 150 mg twice daily (n=329) vs placebo (n=219): -113.59 vs -207.32 mL/year; difference 93.73 mL/year (95% CI 44.78 to 142.68), p = 0.0002 (CT.gov posted results).
Pirfenidone (Esbriet)ApprovedSmall moleculePyridoneReliable signal
NCT01366209: At week 52, decline in percent predicted FVC of 10 points or more, or death: pirfenidone 16.5% vs placebo 31.8% (relative reduction 47.9%); no FVC decline 22.7% vs 9.7%; P<0.001 (ASCEND, NEJM 2014; CT.gov posted results).
Treprostinil (Tyvaso DPI)
Approved(overall)
Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
HSK44459Phase 3Small moleculePDE4Bnot yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso)Phase 3Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
ABBV-722
Phase 1(overall)
Small moleculeLPAR1not yet gradedNo reviewed efficacy summary in this indication
Iloprost (Ventavis)DiscontinuedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
PamrevlumabDiscontinuedMonoclonal antibodyCTGFnot yet gradedNo reviewed efficacy summary in this indication
Voxelotor (Oxbryta)DiscontinuedSmall moleculeHemoglobin S (HbS)not yet gradedNo reviewed efficacy summary in this indication
ZiritaxestatDiscontinuedSmall moleculeautotaxin (ENPP2)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(10 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Nerandomilast (Jascayd) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
Phase 2Interstitial Lung Disease Due to Systemic Disease, SclerodermaRecruiting
Est. primary completion 2026-11 · NCT06195072 · CT.gov ↗
What to watch
2027 (4)
April 2027 (2)
Phase 3Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung DiseasesActive not recruiting
Est. primary completion 2027-04-15 · NCT06806592 · CT.gov ↗
What to watch
Phase 3Idiopathic Pulmonary FibrosisActive not recruiting
Est. primary completion 2027-04-28 · NCT06238622 · CT.gov ↗
What to watch
June 2027 (2)
Phase 4Pulmonary Fibrosis, Interstitial Lung Disease (ILD)Not yet recruiting
Est. primary completion 2027-06 · NCT07570888 · CT.gov ↗
What to watch
Phase 2/3ALS (Amyotrophic Lateral Sclerosis)Not yet recruiting
Est. primary completion 2027-06-30 · NCT07321860 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
Phase 3Interstitial Lung DiseasesRecruiting
Est. primary completion 2028-12-05 · NCT07540988 · CT.gov ↗
What to watch
2029 (2)
April 2029 (1)
Phase 3Fibrosing Interstitial Lung DiseaseRecruiting
Est. primary completion 2029-04-27 · NCT07366034 · CT.gov ↗
What to watch
May 2029 (1)
Phase 3Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung DiseasesRecruiting
Est. primary completion 2029-05-14 · NCT07201922 · CT.gov ↗
What to watch
2030 (2)
February 2030 (1)
Phase 3Systemic SclerosisRecruiting
Est. primary completion 2030-02-26 · NCT07497087 · CT.gov ↗
What to watch
March 2030 (1)
Phase 3Idiopathic Inflammatory MyopathiesNot yet recruiting
Est. primary completion 2030-03-21 · NCT07789015 · CT.gov ↗
What to watch

See the full readout calendar ↗